Cargando…

Olaratumab’s failure in soft tissue sarcoma

Soft tissue sarcomas remain one of the rarest malignancies with numerous subtypes that go undiagnosed. The PDGFRα antagonist Olaratumab (Lartruvo) was withdrawn from the market due to disappointing findings in the phase III studies. We share our experience with this medication in a tertiary care cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Bou Zerdan, Maroun, Bidikian, Aram H, Alameh, Ibrahim, Nakib, Clara El, Assi, Hazem I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293854/
https://www.ncbi.nlm.nih.gov/pubmed/34349891
http://dx.doi.org/10.1177/20363613211034115